<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773786</url>
  </required_header>
  <id_info>
    <org_study_id>ASRC956</org_study_id>
    <nct_id>NCT00773786</nct_id>
  </id_info>
  <brief_title>Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Double-Blind, Crossover Study to Assess the Effects of Nebulized Brovana Added to Tiotropium on FEV1, Hyperinflation, and Exercise Endurance Capacity in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Francis Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Francis Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double-blind crossover trial in 20 patient with stable COPD. Data from this&#xD;
      study will provide proof-of-concept information on whether the (anticipated) additional&#xD;
      bronchodilator effect of Brovana added to tiotropium will lead to a meaningful improvement in&#xD;
      the patient-centered outcome, exercise capacity. This study will only evaluate the effects of&#xD;
      short-term (1-week) administration of Brovana. If results are positive, it would provide&#xD;
      preliminary data for further, multicenter investigations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses to be tested:&#xD;
&#xD;
      Brovana nebulized twice daily added to maintenance inhaled tiotropium therapy in stable COPD&#xD;
      patients increases:&#xD;
&#xD;
        1. Forced expiratory volume in 1 second (FEV1) at peak dose effect (approximately 2 hours&#xD;
           after AM dosing in the laboratory)&#xD;
&#xD;
        2. Resting and exercise hyperinflation at peak dose effect (inspiratory capacity (IC) at&#xD;
           baseline and at iso-time during exercise testing; these measurements will be&#xD;
           approximately 2 ¼ hours after AM dosing of tiotropium plus test drug.&#xD;
&#xD;
        3. Exercise treadmill endurance time at peak dose effect (approximately 2 ¼ hours after AM&#xD;
           dosing in the laboratory)&#xD;
&#xD;
      Patients: Twenty patients will be studied&#xD;
&#xD;
      Location: Section of Pulmonary and Critical Care, St. Francis Hospital &amp; Medical Center,&#xD;
      Hartford, CT&#xD;
&#xD;
      Excluded drugs:&#xD;
&#xD;
        1. Anticholinergic bronchodilators other than once-daily (AM) tiotropium at standard dose&#xD;
&#xD;
        2. Long acting beta agonist bronchodilators&#xD;
&#xD;
        3. Short acting beta agonist bronchodilators must be withheld within six hours of&#xD;
           laboratory testing&#xD;
&#xD;
      Allowed drugs:&#xD;
&#xD;
        1. Inhaled steroids&#xD;
&#xD;
        2. Oral steroids 10 mg/day or less, at stable dose for four weeks&#xD;
&#xD;
      Removal of patients from study:&#xD;
&#xD;
        1. Withdrawal of consent&#xD;
&#xD;
        2. Documented oxygen desaturation &lt; 85% or clinically significant problems (such as angina,&#xD;
           significant electrocardiogram (ECG) changes, etc) during any exercise testing&#xD;
&#xD;
        3. A significant adverse event&#xD;
&#xD;
        4. Protocol violation including lack of adherence&#xD;
&#xD;
      COPD exacerbations during study:&#xD;
&#xD;
      If the patient experiences a COPD exacerbation during the study which requires a change in&#xD;
      medication or an addition of medication (such as oral steroids or antibiotics) the study will&#xD;
      be held until stability is reached. At that time, the study will resume, beginning with new,&#xD;
      1-week treatment /testing corresponding to the study sequence when the exacerbation began. If&#xD;
      the patient does not resume stability within four weeks or has a second exacerbation, the&#xD;
      study will be terminated.&#xD;
&#xD;
      Study design: This will be a double-blind, crossover, single-site study in COPD patients who&#xD;
      are in stable condition. All patients in study randomized to test drug by Visit 2 will have&#xD;
      been on steady-state tiotropium therapy, off commercial long-acting beta-agonists (LABA), and&#xD;
      using prn short-acting beta-agonists (SABA). Only acute (i.e., 1-week) effects of Brovana&#xD;
      will be studied. SABA will be withheld from midnight before testing on each day.&#xD;
&#xD;
      Exercise testing and inspiratory capacity (IC) measurements Incremental and steady-state&#xD;
      endurance testing will be performed on a treadmill in the Section of Pulmonary and Critical&#xD;
      Care Medicine. The incremental test (Visit 1) will be performed to a symptom-limited maximum,&#xD;
      with a goal to have the test duration over approximately 10 minutes. The protocol used for&#xD;
      this will be from Porszasz et al using simultaneous increases in treadmill speed and incline,&#xD;
      with settings based on estimated maximal workrate. Warm-up will be 1 mph at 1% grade. This&#xD;
      will be followed at 30-second intervals by increases in speed and incline. Patients will have&#xD;
      breath by breath measurements of expired air using our Sensormedics equipment, via a&#xD;
      mouthpiece. IC measurements will also be measured at rest and at every minute into exercise.&#xD;
&#xD;
      Endurance tests (Visit 2, 4, 5) will be at 75% of the maximal rate determined from the&#xD;
      initial test. For exercise capacity, duration in exercise time will be the primary outcome&#xD;
      variable. IC will be measured at rest and at every minute during exercise.&#xD;
&#xD;
      An ECG will be performed before each exercise test, and continuous pulse oximetry will be&#xD;
      monitored. A physician will be in attendance at each test.&#xD;
&#xD;
      Primary Efficacy Variables:&#xD;
&#xD;
        1. Change in FEV1 near peak effect (~ 2 hours of AM laboratory dosing of tiotropium plus&#xD;
           test drug):&#xD;
&#xD;
             1. The primary comparison will be Δ FEV1 (@ 2-hours after Tiotropium + Brovana minus&#xD;
                pre-dose FEV1) versus Δ FEV1 (@2-hours after Tiotropium + Placebo minus pre-dose&#xD;
                FEV1)&#xD;
&#xD;
             2. The analysis will be performed using a repeated-measures design, PROC GLM Repeated,&#xD;
                SAS:&#xD;
&#xD;
        2. Change in treadmill endurance time at ~75% of maximum (Δ endurance time) Brovana versus&#xD;
           placebo: from baseline testing on tiotropium alone compared to testing on tiotropium +&#xD;
           study drug.&#xD;
&#xD;
             1. The primary comparison will be Δ endurance time (@ 2 ¼ hours after Tiotropium +&#xD;
                Brovana compared to tiotropium alone&#xD;
&#xD;
             2. The analysis will be performed using a repeated-measures design, PROC GLM Repeated,&#xD;
                SAS&#xD;
&#xD;
        3. Change in static (resting), iso-time, and peak exercise IC measurements, which will be&#xD;
           used as our estimates of hyperinflation; Brovana versus placebo: from baseline testing&#xD;
           on tiotropium alone compared to testing on tiotropium + study drug.&#xD;
&#xD;
           a. The primary co-comparisons will be: i. Δ IC at rest (static hyperinflation) (@ 2 ¼&#xD;
           hours after Tiotropium + Brovana compared to tiotropium alone ii. Δ IC at iso-time&#xD;
           (static hyperinflation) (@ 2 ¼ hours after Tiotropium + Brovana compared to tiotropium&#xD;
           alone. We are not sure what iso-time we will use, but if all patients go six minutes&#xD;
           into exercise, we will use the six minute mark.&#xD;
&#xD;
           b. The analyses will be performed using a repeated-measures design, PROC GLM Repeated,&#xD;
           SAS&#xD;
&#xD;
      Sample Size Estimation The van Noord sited earlier powered their study assuming a ~ 140 mL&#xD;
      standard deviation for paired differences in FEV1 (determined from earlier trials), a&#xD;
      difference of ~ 50 mL, and a power of 0.90. They achieved a 150 mL (0.150 L) difference in&#xD;
      FEV1. For our study, using a difference of 150 mL, a standard deviation of 140 mL, and a&#xD;
      power of 0.80, 16 patients would be sufficient.&#xD;
&#xD;
      In a study by O'Donnell et al the combination of fluticasone 250 mcg / salmeterol 50 mcg was&#xD;
      compared to salmeterol alone and placebo. Outcome variables included spirometry, lung volumes&#xD;
      and exercise endurance time at 75% of maximal on a cycle ergometer. The average improvement&#xD;
      (compared to placebo) in FEV1 at Day 1 (taken from graph) was about 200 mL with both the&#xD;
      combination and salmeterol. The treatment-difference improvement in exercise endurance time&#xD;
      with the combination was 131 ± 31 seconds (p. &lt; 0.004), representing a 22% improvement. For&#xD;
      salmeterol alone it was 49 ± 37 seconds. Our study would use a treadmill rather than a cycle&#xD;
      ergometer; this will probably lead to more dyspnea-limitation than leg fatigue limitation. We&#xD;
      predict the Δ FEV1 at two hours post dosing (compared to tiotropium alone) with Brovana +&#xD;
      tiotropium in our study will ~ 150 mL - a Δ not too dissimilar to the O'Donnell study Δ. To&#xD;
      detect a 90 second difference in endurance time (1/2 way between 131 seconds and 49 seconds),&#xD;
      and assuming a standard deviation (SD) of 35 seconds, our study would be amply powered.&#xD;
&#xD;
      Study Sequence&#xD;
&#xD;
      Visit 1:&#xD;
&#xD;
        1. Informed consent obtained&#xD;
&#xD;
        2. Inclusion/exclusion criteria met&#xD;
&#xD;
        3. History and physical examination performed&#xD;
&#xD;
        4. Post-bronchodilator spirometry for inclusion criteria&#xD;
&#xD;
        5. Patient started on tiotropium, if necessary; tiotropium dispensed, if necessary&#xD;
&#xD;
        6. If necessary: long acting bronchodilators (LABA) discontinued, ipratropium discontinued&#xD;
&#xD;
        7. Levalbuterol MDI dispensed for prn use&#xD;
&#xD;
        8. Appointment given for Visit 1&#xD;
&#xD;
      Visit 2: 1 day (for patients already on tiotropium) to 1 week (those starting tiotropium)&#xD;
      after Visit 1:&#xD;
&#xD;
        1. Brief history and limited physical&#xD;
&#xD;
        2. Spirometry on maintenance tiotropium, before AM dosing and after having SABA withheld&#xD;
           for ~ 6 hours&#xD;
&#xD;
        3. Incremental treadmill endurance test&#xD;
&#xD;
        4. Patient instructed to continue taking tiotropium once daily in the morning (qAM) and&#xD;
           levalbuterol MDI prn&#xD;
&#xD;
        5. Appointment for 2-week follow-up&#xD;
&#xD;
      Visit 3: 1 week after Visit 2, after maintenance tiotropium&#xD;
&#xD;
        1. Brief history and limited physical&#xD;
&#xD;
        2. Pre-bronchodilator spirometry (on maintenance tiotropium, levalbuterol withheld)&#xD;
&#xD;
        3. Tiotropium given (open label)&#xD;
&#xD;
        4. Spirometry 2 hours after tiotropium dosing&#xD;
&#xD;
        5. ECG 2 ¼ hour after tiotropium dosing&#xD;
&#xD;
        6. Endurance treadmill endurance test (including IC measurements) 2 ¼ hour after open-label&#xD;
           tiotropium dosing&#xD;
&#xD;
        7. Nebulizer dispensed&#xD;
&#xD;
        8. Blinded Test drug # 1 dispensed (Brovana or placebo, 20 unit doses), instructions to&#xD;
           take it via nebulizer bid, tiotropium continued qAM, levalbuterol MDI continued prn&#xD;
&#xD;
        9. Appointment for 1 week follow-up&#xD;
&#xD;
      Visit 4: 1 weeks after Visit 3, after test drug # 1&#xD;
&#xD;
        1. Brief history and limited physical&#xD;
&#xD;
        2. Pre-dosing spirometry (on maintenance tiotropium and Test Drug #1, levalbuterol&#xD;
           withheld)&#xD;
&#xD;
        3. Tiotropium and Test Drug # 1 given&#xD;
&#xD;
        4. Spirometry 2 hours after above dosing&#xD;
&#xD;
        5. ECG 2 ¼ hour after above dosing&#xD;
&#xD;
        6. Endurance treadmill endurance test 2 ¼ hour after above dosing&#xD;
&#xD;
        7. Begin wash-out period: Tiotropium open-label plus prn levalbuterol continued; placebo&#xD;
           given via nebulizer, to be taken bid (this part is single-blinded)&#xD;
&#xD;
        8. Appointment for 1 week follow-up&#xD;
&#xD;
      Visit 5: 1 week after Visit 4, after washout&#xD;
&#xD;
        1. Brief history and limited physical&#xD;
&#xD;
        2. Spirometry in AM&#xD;
&#xD;
        3. Blinded Test drug # 2 dispensed (Brovana or placebo, 20 unit doses), instructions to&#xD;
           take it via nebulizer bid, tiotropium continued qAM, levalbuterol MDI continued prn&#xD;
&#xD;
        4. Appointment for 1 week follow-up&#xD;
&#xD;
      Visit 6: 1 week after Visit 5, after test drug # 2&#xD;
&#xD;
        1. Brief history and limited physical&#xD;
&#xD;
        2. Pre-dosing spirometry (on maintenance tiotropium and Test Drug #2, levalbuterol&#xD;
           withheld)&#xD;
&#xD;
        3. Tiotropium and Test Drug #2 given&#xD;
&#xD;
        4. Spirometry 2 hours after above dosing&#xD;
&#xD;
        5. ECG 2 ¼ hour after above dosing&#xD;
&#xD;
        6. Endurance treadmill endurance test and IC measurements 2 ¼ hour after above dosing&#xD;
&#xD;
        7. Study terminated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inspiratory Capacity at 1 Week</measure>
    <time_frame>baseline and 2 hours after dosing</time_frame>
    <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Arformoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol twice daily for 1 week via nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol (Brovana)</intervention_name>
    <description>twice daily via nebulizer added to maintenance daily tiotropium</description>
    <arm_group_label>Arformoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily for 1 week (added to maintenance tiotropium)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent (Approval by the St. Francis Hospital Institutional Review Board&#xD;
             (IRB) will be required before study initiation)&#xD;
&#xD;
          2. Adults, age &gt; 40 years&#xD;
&#xD;
          3. A clinical diagnosis of COPD, with spirometric confirmation: post-bronchodilator&#xD;
             forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC) ( &lt; 0.70&#xD;
&#xD;
          4. Moderate, severe and very severe airflow limitation by GOLD criteria.&#xD;
&#xD;
          5. Clinically stable respiratory disease&#xD;
&#xD;
          6. The perceived ability to participate in pulmonary testing and exercise testing&#xD;
&#xD;
          7. COPD, stable state&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Women of childbearing potential&#xD;
&#xD;
          2. Asthma&#xD;
&#xD;
          3. Supplemental oxygen use or anticipated oxygen desaturation &lt; 85% at peak exercise&#xD;
             (patients who desaturate below 85% on the incremental study will be excluded)&#xD;
&#xD;
          4. Co-morbidity that would interfere with the patient participating in the study,&#xD;
             including the exercise testing. Examples include unstable cardiac disease, arthritis,&#xD;
             psychological problems that would interfere with participation&#xD;
&#xD;
          5. An exacerbation requiring therapy or any change in maintenance COPD therapy within six&#xD;
             weeks of testing&#xD;
&#xD;
          6. A history of a prolonged QT interval&#xD;
&#xD;
          7. Recent exacerbation of COPD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard ZuWallack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Frnacis Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Francis Hospital and Medical center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <results_first_submitted>May 29, 2013</results_first_submitted>
  <results_first_submitted_qc>May 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Bronchodilator</keyword>
  <keyword>arformoterol</keyword>
  <keyword>tiotropium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium + Arformoterol (Brovana), Then Tiotropium + Placebo</title>
          <description>Participants first received Tiotropium + Brovana twice daily for 1 week via nebulizer. After a 1 week washout period, they received Tiotropium + placebo twice daily for 1 week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Arformoterol (Brovana)</title>
          <description>Participants first received Tiotropium + Placebo twice daily for 1 week . After a 1 week washout period, they received Tiotropium + Brovana twice daily for 1 week via nebulizer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants randomized and received either Tiotropium + Brovana twice daily for 1 week or Tiotropium + placebo twice daily for 1 week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second (FEV1)</title>
          <units>percent-predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</title>
        <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
        <time_frame>baseline and 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</title>
          <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" spread="0.048"/>
                    <measurement group_id="O2" value="0.010" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.037"/>
                    <measurement group_id="O2" value="0.023" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</title>
        <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
        <time_frame>baseline and 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</title>
          <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0120" spread="0.072"/>
                    <measurement group_id="O2" value="0.000" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.062"/>
                    <measurement group_id="O2" value="-0.062" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inspiratory Capacity at 1 Week</title>
        <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
        <time_frame>baseline and 2 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inspiratory Capacity at 1 Week</title>
          <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.898"/>
                    <measurement group_id="O2" value="-0.019" spread="0.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.063"/>
                    <measurement group_id="O2" value="-0.004" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One week for each intervention</time_frame>
      <desc>Adverse event data was collection on all participants randomized into an intervention</desc>
      <group_list>
        <group group_id="E1">
          <title>Arformoterol</title>
          <description>Arformoterol twice daily for 1 week via nebulizer</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo twice daily for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard ZuWallack, MD</name_or_title>
      <organization>Saint Francis Hospital and Medical Center</organization>
      <email>rzuwalla@stfranciscare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

